Skip to content

Author

Shuang Huang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study

Background In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended...

C. Rudin, M.-J. Ahn, M. Schuler et al. · 0 citations
Open access Sep 2026

Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation. Patients were randomized to tarlatamab or amrubicin in Japan. The prima...

Takayasu Kurata, Shunichi Sugawara, Hiroaki Akamatsu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.